- Home
- IPHA
IPHA
Innate Pharma S.A. ADS
as 11-15-2024 4:00pm EST
| Founded: | 1999 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | 2019 |
| Target Price: | $11.50 | AVG Volume (30 days): | 9.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.44 - $3.15 | Next Earning Date: | 09-12-2024 |
| Revenue: | $36,202,722 | Revenue Growth: | -35.37% |
| Revenue Growth (this year): | -42.12% | Revenue Growth (next year): | 102.87% |
Latest Innate Pharma S.A. ADS News
IPHA Breaking Stock News: Dive into IPHA Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
Discover 3 Promising Penny Stocks With Over US$90M Market Cap
Business Wire
5 days ago
Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
Business Wire
10 days ago
Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
Business Wire
11 days ago
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
Business Wire
20 days ago
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
MT Newswires
a month ago
Innate Pharma Names Jonathan Dickinson as New CEO, Chairman
Business Wire
a month ago
Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
Business Wire
2 months ago
Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
Compare IPHA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IPHA Innate Pharma S.A. ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.